Bausch + Lomb Corporation
基本情報
- 所在地
- Vaughan, ON, Canada
- 社長
- Brent Saunders
- 従業員数(単独)
- 従業員数(連結)
- 開始日
- 終了日
サイト
事業内容
関連会社
関連図
沿革
J. J. Bausch opens an optical goods store in Rochester, New York. He borrows $60 from friend Henry Lomb to expand the business, sealing the deal with a handshake.![]()
J. J. Bausch’s revolutionary Vulcanite eyeglass frames become the first great success for the young company.![]()
Edward Bausch, J. J.’s son, patents the “between the lens” iris diaphragm and shutter, helping to give rise to snapshot photography.![]()
Bausch + Lomb introduces Honorary Science Award for high school students; hundreds of thousands of awards have been bestowed since.![]()
The first films made with the CinemaScope lens premiered in movie theaters, bringing widescreen movie projection to the big screen.![]()
Bausch + Lomb receives an Honorary Award from the Academy of Motion Picture Arts and Sciences for contributions to the advancement of the motion-picture industry.![]()
Bausch + Lomb launches SofLens® contact lenses, the first mass-produced soft contact lens in the United States.![]()
The company creates its first toric contact lens, and the following year launches its first bifocal contact lens.![]()
Polymer Technology Corporation, a leader in rigid gas permeable contact lenses and solutions, is acquired; the Boston® contact lenses and solutions brands join the Bausch + Lomb portfolio.![]()
Bausch + Lomb expands into ophthalmic pharmaceuticals by acquiring Dr. Mann Pharma, and then the following year, Pharmafair Inc.![]()
Bausch + Lomb releases 15 new pharmaceutical products, greatly expanding its pharmaceutical portfolio.![]()
Bausch + Lomb establishes a surgical business unit through acquisitions of Chiron Vision and Storz® Ophthalmics, focusing on cataract, refractive and vitreoretinal surgery.![]()
LOTEMAX® (loteprednol etabonate ophthalmic suspension) 0.5% and Alrex® (loteprednol etabonate ophthalmic suspension) 0.2% are launched.![]()
PureVision® contact lenses, the first silicone hydrogel contact lenses in the United States, are launched.![]()
Bausch + Lomb launches PreserVision® brand of eye vitamins, after supporting the landmark National Eye Institute AREDS study.![]()
Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg is approved by the FDA as an orphan drug.![]()
Eyeonics is acquired, adding Crystalens® IOL—the first FDA-approved accommodating intraocular lens for the treatment of cataracts to the Bausch + Lomb portfolio.![]()
Bausch + Lomb completes the acquisition of ISTA Pharmaceuticals and adds Bromday® (bromfenac ophthalmic solution) 0.09%, Bepreve® (bepotastine besilate ophthalmic solution) 1.5%, Istalol® (timolol maleate ophthalmic solution) 0.5%, and Vitrase® (hyaluronidase for injection) to its product portfolio.![]()
Bausch + Lomb and Technolas Perfect Vision receive FDA clearance for Victus® Femtosecond Laser Platform.![]()
Bausch + Lomb ULTRA® silicone hydrogel monthly contact lenses and Biotrue® ONEday for Presbyopia contact lenses are introduced.![]()
Synergetics USA Inc. and Acrivet are acquired, expanding the surgical product portfolio to include retina surgery products and veterinary ophthalmic products, respectively.![]()
Acquisition of Alden Optical Laboratories increases access to specialty modalities, including the Zenlens™ scleral lens and NovaKone® soft contact lens for keratoconus.![]()
First-in-class eyeTELLIGENCE™ application is now available exclusively on the Stellaris Elite® vision enhancement system.![]()
Bausch + Lomb launches LUMIFY® redness reliever eye drops, the first and only over-the-counter eye drop with low-dose brimonidine tartrate for the relief of eye redness.![]()
LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% receives FDA approval; enVista® toric MX60ET hydrophobic acrylic intraocular lens (IOL) with StableFlex™ technology is launched.![]()
Bausch + Lomb receives FDA approval for ClearVisc™ dispersive ophthalmic viscosurgical device (OVD).![]()
ニュース
ニュースはありません。